Skip to main content

Summit Therapeutics

Summit Therapeutics Inc is an American biopharmaceutical company developing novel oncology therapies. The company's lead candidate, ivonescimab, is a bispecific antibody combining anti-PD-1 and anti-VEGF mechanisms designed to improve outcomes in non-small cell lung cancer and other solid tumors. Main revenue drivers currently comprise development partnership milestones, licensing agreements, and capital markets financing as Phase III clinical trials advance. Summit Therapeutics targets medical oncologists, clinical research hospitals, biopharmaceutical partners, and lung cancer patients across North America, South America, and Europe. The company holds a prominent market position in bispecific antibody development for precision oncology. Headquartered in Miami, Florida, Summit Therapeutics Inc is listed on the Nasdaq Stock Market.

5 of the funds FundTelligence covers report a position in Summit Therapeutics.

Legal name
Summit Therapeutics Inc
Sector
Health Care
Country
United States
Funds holding it
5

Funds holding Summit Therapeutics

Loading...